As on December 2023, Apollo Therapeutics LLP closed the transaction. The company has received additional $33.5 million in its second tranche was led by Patient Square Capital, LP. The transaction included participation from returning investor, Rock Springs Capital Management LP and from new investors, M&G plc and two of the largest US public pension plans.

The company has raised $260 million in funding so far in the transaction. The transaction has issued common shares.